AIRLINK 195.89 Increased By ▲ 2.33 (1.2%)
BOP 10.07 Increased By ▲ 0.12 (1.21%)
CNERGY 7.85 Decreased By ▼ -0.08 (-1.01%)
FCCL 40.01 Decreased By ▼ -0.64 (-1.57%)
FFL 17.01 Increased By ▲ 0.15 (0.89%)
FLYNG 27.15 Decreased By ▼ -0.60 (-2.16%)
HUBC 133.50 Increased By ▲ 0.92 (0.69%)
HUMNL 14.15 Increased By ▲ 0.26 (1.87%)
KEL 4.67 Increased By ▲ 0.07 (1.52%)
KOSM 6.69 Increased By ▲ 0.07 (1.06%)
MLCF 47.18 Decreased By ▼ -0.42 (-0.88%)
OGDC 215.01 Increased By ▲ 1.10 (0.51%)
PACE 6.97 Increased By ▲ 0.04 (0.58%)
PAEL 41.81 Increased By ▲ 0.57 (1.38%)
PIAHCLA 17.20 Increased By ▲ 0.05 (0.29%)
PIBTL 8.52 Increased By ▲ 0.11 (1.31%)
POWER 9.67 Increased By ▲ 0.03 (0.31%)
PPL 184.20 Increased By ▲ 1.85 (1.01%)
PRL 42.90 Increased By ▲ 0.94 (2.24%)
PTC 25.15 Increased By ▲ 0.25 (1%)
SEARL 109.65 Increased By ▲ 2.81 (2.63%)
SILK 1.01 Increased By ▲ 0.02 (2.02%)
SSGC 44.11 Increased By ▲ 4.01 (10%)
SYM 17.80 Increased By ▲ 0.33 (1.89%)
TELE 8.99 Increased By ▲ 0.15 (1.7%)
TPLP 13.00 Increased By ▲ 0.25 (1.96%)
TRG 67.49 Increased By ▲ 0.54 (0.81%)
WAVESAPP 11.68 Increased By ▲ 0.35 (3.09%)
WTL 1.82 Increased By ▲ 0.03 (1.68%)
YOUW 3.99 Decreased By ▼ -0.08 (-1.97%)
BR100 12,223 Increased By 178.5 (1.48%)
BR30 36,950 Increased By 370.2 (1.01%)
KSE100 115,297 Increased By 1259 (1.1%)
KSE30 36,278 Increased By 483.6 (1.35%)
Markets

Bayer to cut more than 1.5bn euros in costs

  • The cash flow freed up would be allocated for investments in further innovation, profitable growth opportunities and debt reduction.
  • Bayer said it expects 2021 sales to be about the same as in 2020, despite significant headwinds from COVID-19.
Published September 30, 2020

BERLIN: German drugs company Bayer AG announced plans on Wednesday for more than 1.5 billion euros ($1.76 billion)of cost cuts as of 2024, on top of savings announced in 2018, as it battles with a slowdown in the agricultural market.

The cash flow freed up would be allocated for investments in further innovation, profitable growth opportunities and debt reduction. It said the restructuring, which may also lead to extra job cuts, is in the early stages of planning.

Bayer said it expects 2021 sales to be about the same as in 2020, despite significant headwinds from COVID-19, especially in the agricultural market, and said it expects core earnings per share to be slightly lower at constant exchange rates.

Comments

Comments are closed.